ArticleNorthern clinics of Istanbul2024
The relationship between the degree of visceral pleural invasion and survival in non-small cell lung cancer.
Article in Northern clinics of Istanbul, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of segmentectomy and lobectomy for non-small cell lung cancer with visceral pleural invasion.Journal of cardiothoracic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the relationship between the degree of visceral pleural invasion (VPI) and survival in patients operated for non-small cell lung cancer (NSCLC).
methodsBetween 2013 and 2015, 202 patients who were diagnosed with NSCLC in our center and followed up in our clinic were retrospectively evaluated. To examine the preoperative and postoperative prognostic factors of the patients, postoperative pathology results, demographic data and data on recurrence status were obtained from our hospital database and patient files.
resultsVPI Survival analysis was performed by dividing 3 groups: PL0, PL1 and PL2. Mean survival (MS) was calculated as 39.528±1.469 (36.655-42.402; 95% CI) months for PL0, 35.136±3.115 (29.031-41.240; 95% CI) months for PL1, and 24.688±3.697 (17.441-31.934; 95% CI) for PL2 (p=0.020). When we consider PL0 and PL1 as a single group and compare it with PL2, the MS time of the PL0-PL1 group was 38.358±1.346 (35.721-40.995; 95% CI) months, while the MS time of the PL2 group was 24.688±3.697 (17.441-31.934; 95% CI) months (p=0.020).
conclusionAlthough PL0, PL1 and PL2 were classified into a single group (all considered as T2), this study showed that the presence of PL2 was associated with a poor prognosis in terms of survival, independent of lymph node involvement, histopathological subtype of the tumor and tumor size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.